BridgeBio Pharma Inc (NASDAQ:BBIO) — Market Cap & Net Worth
Market Cap & Net Worth: BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc (NASDAQ:BBIO) has a market capitalization of $13.14 Billion ($13.14 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1796 globally and #662 in its home market, demonstrating a -4.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BridgeBio Pharma Inc's stock price $68.56 by its total outstanding shares 191626988 (191.63 Million). Analyse BridgeBio Pharma Inc (BBIO) cash conversion ratio to see how efficiently the company converts income to cash.
BridgeBio Pharma Inc Market Cap History: 2019 to 2026
BridgeBio Pharma Inc's market capitalization history from 2019 to 2026. Data shows growth from $6.72 Billion to $13.14 Billion (14.24% CAGR).
Index Memberships
BridgeBio Pharma Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.54% | #29 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.03% | #206 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.79% | #20 of 263 |
Weight: BridgeBio Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BridgeBio Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BridgeBio Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
23.70x
BridgeBio Pharma Inc's market cap is 23.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $6.72 Billion | $40.56 Million | -$260.44 Million | 165.59x | N/A |
| 2020 | $13.63 Billion | $8.25 Million | -$448.72 Million | 1651.91x | N/A |
| 2021 | $3.20 Billion | $69.72 Million | -$562.54 Million | 45.85x | N/A |
| 2022 | $1.46 Billion | $77.65 Million | -$481.18 Million | 18.81x | N/A |
| 2023 | $7.74 Billion | $9.30 Million | -$643.20 Million | 831.56x | N/A |
| 2024 | $5.26 Billion | $221.90 Million | -$535.76 Million | 23.70x | N/A |
Competitor Companies of BBIO by Market Capitalization
Companies near BridgeBio Pharma Inc in the global market cap rankings as of May 4, 2026.
Key companies related to BridgeBio Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BridgeBio Pharma Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, BridgeBio Pharma Inc's market cap moved from $6.72 Billion to $ 13.14 Billion, with a yearly change of 14.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.14 Billion | -10.37% |
| 2025 | $14.66 Billion | +178.75% |
| 2024 | $5.26 Billion | -32.03% |
| 2023 | $7.74 Billion | +429.79% |
| 2022 | $1.46 Billion | -54.32% |
| 2021 | $3.20 Billion | -76.54% |
| 2020 | $13.63 Billion | +102.88% |
| 2019 | $6.72 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of BridgeBio Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.14 Billion USD |
| MoneyControl | $13.14 Billion USD |
| MarketWatch | $13.14 Billion USD |
| marketcap.company | $13.14 Billion USD |
| Reuters | $13.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM);… Read more